Cargando…

Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up

Rheumatoid arthritis (RA) is a joint-disabling inflammatory disease associated with the pathology of synovitis. Some patients with RA are difficult to treat, using disease-modifying anti-rheumatic drugs (DMARDs). Biology and targeted synthetic DMARDs (b/tsDMARDs) are options for patients with RA. Ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jing-Wen, Deng, Guo-Shu, Zhang, Wen-Shuang, Zhang, Ming-Ying, Guan, Tong, Xu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382239/ https://www.ncbi.nlm.nih.gov/pubmed/35990692 http://dx.doi.org/10.3389/fimmu.2022.942642

Ejemplares similares

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
por: Chen, Jing-Wen, et al.
Publicado: (2022)

EULAR definition of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2021)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis
por: Majnik, Judit, et al.
Publicado: (2022)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2022)

Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems
por: Watanabe, Ryu, et al.
Publicado: (2022)

Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis
por: Paoletti, Audrey, et al.
Publicado: (2022)

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Low Percentage of Signal Regulatory Protein α/β(+) Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients
por: Magill, Laura, et al.
Publicado: (2018)

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
por: Tan, Yvonne, et al.
Publicado: (2022)

Targeting matrix metalloproteases: A promising strategy for herbal medicines to treat rheumatoid arthritis
por: Li, Ruo-Lan, et al.
Publicado: (2022)

Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients
por: Novella-Navarro, Marta, et al.
Publicado: (2022)

An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients
por: Ito, Satoshi, et al.
Publicado: (2018)

Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
por: Kim, Seong-Kyu, et al.
Publicado: (2023)

OA20 Combining B cell depletion and JAKi for difficult-to-treat rheumatoid arthritis
por: Lee, Sook Yan, et al.
Publicado: (2023)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Adalimumab in Treating Refractory Livedoid Vasculopathy
por: Huang, Xiao-Wen, et al.
Publicado: (2022)

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease
por: Leon, Leticia, et al.
Publicado: (2023)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2023)

Mini-Review: The Administration of Apoptotic Cells for Treating Rheumatoid Arthritis: Current Knowledge and Clinical Perspectives
por: Toussirot, Eric, et al.
Publicado: (2021)

Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
por: Chen, Peng-Yu, et al.
Publicado: (2023)

Epigenetic Regulation in the Pathogenesis of Rheumatoid Arthritis
por: Yang, Chao, et al.
Publicado: (2022)

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
por: Capsoni, Franco, et al.
Publicado: (2005)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021)

Lupus Cardiomyopathy and Nephritis Associated With Adalimumab and Cytomegalovirus Infection in a Patient With Seronegative Rheumatoid Arthritis: A Case of Rhupus Syndrome
por: Waitayangkoon, Palapun, et al.
Publicado: (2023)

Reestablish immune tolerance in rheumatoid arthritis
por: Shuai, Ziqiang, et al.
Publicado: (2022)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_n9otb85lr11ke4ac7q2g74t3o4